Saying it is on track to exceed its goal of having 5 key products in clinical development through 2015, Alnylam recently announced that it intends to focus on three strategic therapeutic areas, or what it dubs "STArs," as it races to commercialize its first candidate delivered using the RNAi pathway and reassure sometimes antsy investors.
BOSTON--Talking of breaking internal silos has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKline's ($GSK) head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference. Read more >>
The prospects for Remoxy, the twice-rejected, investigational, extended-release oral formulation of oxycodone, look bleak. Pfizer is pulling out of a partnership with Durect to commercialize the candidate, after reviewing the results of 5 clinical trials conducted in response to the FDA's second complete response letter, issued in 2011. Read more >>
POPULAR COMMENT THREADS
Microchips Biotech says it's ready to send its delivery technology out into the world, this week announcing it has completed development and clinical demonstration of the drug-delivering implant.
Arrowhead Research Corporation is looking to add another entrant into the clinical trial-based race to commercialize the first RNAi-based compound, a market category that could become a new class of drugs akin to monoclonal antibodies and produce revenues exceeding $1 billion by 2020 according to one projection. The company recently announced that it has submitted its Investigational New Drug application for its RNAi candidate, ARC-520, for the treatment of the chronic hepatitis B virus.
The evidence is clear: Patients don't properly use drug delivery devices like inhalers or epinephrine autoinjectors--such as Mylan's EpiPen.
Researchers have found a way to sneak peptides past the immune system by fitting them with cages that cover binding sites on the proteins like a hat. These prevent the binding sites from revealing the peptides' true nature as something from the outside.
The FDA approved Sanofi's Fluzone Intradermal Quadrivalent in adults age 18 through 64.
Researchers at the University of Maryland and Bethesda, MD-based Weinberg Medical Physics have created a startup called Iron Focus Medical that attempts to build on their prior research to commercialize a novel drug delivery system.
From Our Sister Sites
Pharmaceutical call center applicants should come prepared with an impressive resume, as more companies are turning to experienced professionals to field questions from consumers, according to a new survey by pharma business intelligence provider Cutting Edge Information.
Home healthcare is a buzz word these days, and with good justification, including the aging population and a growing focus on cost-cutting within the healthcare system. Medical device companies are responding in kind. In the latest example, NxStage Medical won an expanded indication from the FDA for overnight, home use of its System One hemodialysis system.